Login Register Cart 0
Generic placeholder image

Current Molecular Medicine

Editor-in-Chief

ISSN (Print): 1566-5240
ISSN (Online): 1875-5666

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

USP3 inhibition is Active Against Chemo-resistant Hepatocellular Carcinoma Anchorage-independent Growth via Suppressing Wnt/β-catenin

Author(s): Jianguo Xu, Ge Sang Wang Gui, Chao Yang, Shuchen Zhu, Zemin Chen, Suo Lang Bai Ma, Ci Yang, Ci Ren Luo Bu, Ying Zhu* and Wen Xu*

Volume 24, Issue 5, 2024

Published on: 30 October, 2023

Page: [667 - 675] Pages: 9

DOI: 10.2174/0115665240258296231024112309

Price: $65

conference banner
Abstract

Background: USPs are a family of enzymes that regulate protein degradation, and their dysregulation has been implicated in the development and progression of cancer.

Aims: This study aimed to determine whether ubiquitin-specific proteases 3 (USP3) could be a potential target for therapy in hepatocellular carcinoma (HCC), particularly in resistant HCC. This study systematically investigated the role of USP3 in HCC, with a focus on chemo-resistant HCC cells.

Methods: The level of USP3 from clinical samples was measured using an ELISA assay. Cell proliferation, apoptosis, migration, and anchorage-independent colony formation assays were performed. Transfection was performed to knock down USP3 expression and measure β-catenin activity, and real-time PCR was used to measure levels of MYC and CYCLIN D1 genes.

Results: USP3 protein was upregulated in HCC tissues, but its upregulation was not associated with clinicopathology. USP3 knockdown had a similar inhibitory effect on growth in both sensitive and resistant HCC cells, did not affect migration, and induced apoptosis in sensitive but not resistant HCC cells. Furthermore, USP3 knockdown was more effective in suppressing anchorage-independent colony formation in chemoresistant HCC cells compared to their chemo-sensitive counterparts. Pearson correlation coefficient analysis revealed a strong positive correlation between USP3 and CTNNB1, and consistently, USP3 knockdown reduced the levels and activities of β-catenin in HCC cells. Using a Wnt activator (lithium) in rescue studies significantly reversed the inhibitory effects of USP3 knockdown.

Conclusion: The findings suggest that inhibiting USP3 is an effective strategy against cancer stem cells and chemo-resistant HCC cells.

« Previous Next »
[1]
Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. Lancet 2022; 400(10360): 1345-62.
[http://dx.doi.org/10.1016/S0140-6736(22)01200-4] [PMID: 36084663]
[2]
Yang C, Zhang H, Zhang L, et al. Evolving therapeutic landscape of advanced hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2023; 20(4): 203-22.
[http://dx.doi.org/10.1038/s41575-022-00704-9] [PMID: 36369487]
[3]
Chakraborty E, Sarkar D. Emerging therapies for Hepatocellular Carcinoma (HCC). Cancers 2022; 14(11): 2798.
[http://dx.doi.org/10.3390/cancers14112798] [PMID: 35681776]
[4]
Antao AM, Tyagi A, Kim KS, Ramakrishna S. Advances in deubiquitinating enzyme inhibition and applications in cancer therapeutics. Cancers 2020; 12(6): 1579.
[http://dx.doi.org/10.3390/cancers12061579] [PMID: 32549302]
[5]
Young MJ, Hsu KC, Lin TE, Chang WC, Hung JJ. The role of ubiquitin-specific peptidases in cancer progression. J Biomed Sci 2019; 26(1): 42.
[http://dx.doi.org/10.1186/s12929-019-0522-0] [PMID: 31133011]
[6]
Isik A, Ramanathan R. Approaches to the treatment of pilonidal sinus disease, clinical practice in 2019. Int Wound J 2020; 17(2): 508-9.
[http://dx.doi.org/10.1111/iwj.13265] [PMID: 31710171]
[7]
Isik A, Kurnaz E, Isik NA. Intermammary pilonidal disease. J Galician Med 2019; 26(2): 265-8.
[http://dx.doi.org/10.21802/gmj.2019.2.11]
[8]
Li Y, Xu Y, Gao C, et al. USP1 maintains the survival of liver circulating tumor cells by deubiquitinating and stabilizing TBLR1. Front Oncol 2020; 10: 554809.
[http://dx.doi.org/10.3389/fonc.2020.554809]
[9]
Chen Z, Ma Y, Guo Z, Song D, Chen Z, Sun M. Ubiquitin specific protease 1 acts as an oncogene and promotes lenvatinib efficacy in hepatocellular carcinoma by stabilizing c-kit. Ann Hepatol 2022; 27(2): 100669.
[http://dx.doi.org/10.1016/j.aohep.2022.100669] [PMID: 35045360]
[10]
Nadolny C, Zhang X, Chen Q, et al. Dysregulation and activities of ubiquitin specific peptidase 2b in the pathogenesis of hepatocellular carcinoma. Am J Cancer Res 2021; 11(10): 4746-67.
[PMID: 34765291]
[11]
Qiu C, Liu Y, Mei Y, et al. Ubiquitin-specific protease 4 promotes metastasis of hepatocellular carcinoma by increasing TGF-β signaling-induced epithelial-mesenchymal transition. Aging 2018; 10(10): 2783-99.
[http://dx.doi.org/10.18632/aging.101587] [PMID: 30335615]
[12]
Zhang W, Zhang J, Xu C, et al. Ubiquitin-specific protease 7 is a drug-able target that promotes hepatocellular carcinoma and chemoresistance. Cancer Cell Int 2020; 20: 28.
[http://dx.doi.org/10.1186/s12935-020-1109-2]
[13]
Liu Y, Wang WM, Lu YF, et al. Usp5 functions as an oncogene for stimulating tumorigenesis in hepatocellular carcinoma. Oncotarget 2017; 8(31): 50655-64.
[http://dx.doi.org/10.18632/oncotarget.16901] [PMID: 28881591]
[14]
Zhu Y, Xu J, Hu W, et al. Inhibiting USP8 overcomes hepatocellular carcinoma resistance via suppressing receptor tyrosine kinases. Aging 2021; 13(11): 14999-5012.
[http://dx.doi.org/10.18632/aging.203061] [PMID: 34081623]
[15]
Xu J, Zhu Y, Wang F, Zhou Y, Xia G, Xu W. ICMT contributes to hepatocellular carcinoma growth, survival, migration and chemoresistance via multiple oncogenic pathways. Biochem Biophys Res Commun 2019; 518(3): 584-9.
[http://dx.doi.org/10.1016/j.bbrc.2019.08.094] [PMID: 31451223]
[16]
Gao CF, Xie Q, Su YL, et al. Proliferation and invasion: Plasticity in tumor cells. Proc Natl Acad Sci 2005; 102(30): 10528-33.
[http://dx.doi.org/10.1073/pnas.0504367102]
[17]
Batlle E, Clevers H. Cancer stem cells revisited. Nat Med 2017; 23(10): 1124-34.
[http://dx.doi.org/10.1038/nm.4409] [PMID: 28985214]
[18]
Clément-Lacroix P, Ai M, Morvan F, et al. Lrp5-independent activation of Wnt signaling by lithium chloride increases bone formation and bone mass in mice. Proc Natl Acad Sci 2005; 102(48): 17406-11.
[http://dx.doi.org/10.1073/pnas.0505259102] [PMID: 16293698]
[19]
Fan L, Chen Z, Wu X, et al. Ubiquitin-specific protease 3 promotes glioblastoma cell invasion and epithelial-mesenchymal transition via stabilizing snail. Mol Cancer Res 2019; 17(10): 1975-84.
[http://dx.doi.org/10.1158/1541-7786.MCR-19-0197] [PMID: 31266817]
[20]
Wu X, Liu M, Zhu H, et al. Ubiquitin-specific protease 3 promotes cell migration and invasion by interacting with and deubiquitinating SUZ12 in gastric cancer. J Exp Clin Cancer Res 2019; 38(1): 277.
[http://dx.doi.org/10.1186/s13046-019-1270-4] [PMID: 31234902]
[21]
Liao XH, Wang Y, Zhong B, Zhu SY. USP3 promotes proliferation of non-small cell lung cancer through regulating RBM4. Eur Rev Med Pharmacol Sci 2020; 24(6): 3143-51.
[http://dx.doi.org/10.26355/eurrev_202003_20681] [PMID: 32271432]
[22]
Wu Y, Qin J, Li F, et al. USP3 promotes breast cancer cell proliferation by deubiquitinating KLF5. J Biol Chem 2019; 294(47): 17837-47.
[http://dx.doi.org/10.1074/jbc.RA119.009102] [PMID: 31624151]
[23]
Wu X, Wang H, Zhu D, et al. USP3 promotes gastric cancer progression and metastasis by deubiquitination-dependent COL9A3/COL6A5 stabilisation. Cell Death Dis 2021; 13(1): 10.
[http://dx.doi.org/10.1038/s41419-021-04460-7] [PMID: 34930901]
[24]
Lancini C, van den Berk PCM, Vissers JHA, et al. Tight regulation of ubiquitin-mediated DNA damage response by USP3 preserves the functional integrity of hematopoietic stem cells. J Exp Med 2014; 211(9): 1759-77.
[http://dx.doi.org/10.1084/jem.20131436] [PMID: 25113974]
[25]
Wang Z, Yang J, Di J, et al. Downregulated USP3 mRNA functions as a competitive endogenous RNA of SMAD4 by sponging miR-224 and promotes metastasis in colorectal cancer. Sci Rep 2017; 7(1): 4281.
[http://dx.doi.org/10.1038/s41598-017-04368-3] [PMID: 28655924]
[26]
Rhie BH, Antao AM, Karapurkar JK, et al. Ubiquitin-specific protease 3 deubiquitinates and stabilizes oct4 protein in human embryonic stem cells. Int J Mol Sci 2021; 22(11): 5584.
[http://dx.doi.org/10.3390/ijms22115584] [PMID: 34070420]
[27]
Leung HW, Leung CON, Lau EY, et al. EPHB2 activates β-catenin to enhance cancer stem cell properties and drive sorafenib resistance in hepatocellular carcinoma. Cancer Res 2021; 81(12): 3229-40.
[http://dx.doi.org/10.1158/0008-5472.CAN-21-0184] [PMID: 33903122]
[28]
Xu C, Xu Z, Zhang Y, Evert M, Calvisi DF, Chen X. β-Catenin signaling in hepatocellular carcinoma J Clin Invest 2022; 132(4): e154515.
[http://dx.doi.org/10.1172/JCI154515] [PMID: 35166233]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy